IGM Biosciences Statistics

Total Valuation

IGM Biosciences has a market cap or net worth of $69.73 million. The enterprise value is -$38.42 million.

Market Cap	69.73M
Enterprise Value	-38.42M

Important Dates

The next estimated earnings date is Wednesday, August 13, 2025, before market open.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	n/a

Share Statistics

IGM Biosciences has 60.12 million shares outstanding. The number of shares has increased by 8.10% in one year.

Current Share Class	34.73M
Shares Outstanding	60.12M
Shares Change (YoY)	+8.10%
Shares Change (QoQ)	+0.52%
Owned by Insiders (%)	2.51%
Owned by Institutions (%)	10.18%
Float	11.07M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	26.30
Forward PS	4.22
PB Ratio	99.81
P/TBV Ratio	99.90
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.71, with a Debt / Equity ratio of 62.98.

Current Ratio	5.71
Quick Ratio	5.43
Debt / Equity	62.98
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -245.59% and return on invested capital (ROIC) is -86.87%.

Return on Equity (ROE)	-245.59%
Return on Assets (ROA)	-36.78%
Return on Invested Capital (ROIC)	-86.87%
Return on Capital Employed (ROCE)	-96.00%
Revenue Per Employee	$17,993
Profits Per Employee	-$1.33M
Employee Count	149
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -84.11% in the last 52 weeks. The beta is 0.51, so IGM Biosciences's price volatility has been lower than the market average.

Beta (5Y)	0.51
52-Week Price Change	-84.11%
50-Day Moving Average	1.24
200-Day Moving Average	6.06
Relative Strength Index (RSI)	41.75
Average Volume (20 Days)	213,215

Short Selling Information

The latest short interest is 773,449, so 1.29% of the outstanding shares have been sold short.

Short Interest	773,449
Short Previous Month	988,761
Short % of Shares Out	1.29%
Short % of Float	6.98%
Short Ratio (days to cover)	4.61

Income Statement

In the last 12 months, IGM Biosciences had revenue of $2.68 million and -$198.87 million in losses. Loss per share was -$3.27.

Revenue	2.68M
Gross Profit	-129.42M
Operating Income	-171.55M
Pretax Income	-236.33M
Net Income	-198.87M
EBITDA	-162.34M
EBIT	-171.55M
Loss Per Share	-$3.27

Full Income Statement

Balance Sheet

The company has $152.11 million in cash and $43.96 million in debt, giving a net cash position of $108.15 million or $1.80 per share.

Cash & Cash Equivalents	152.11M
Total Debt	43.96M
Net Cash	108.15M
Net Cash Per Share	$1.80
Equity (Book Value)	698,000
Book Value Per Share	0.01
Working Capital	132.84M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$143.10 million and capital expenditures -$3.40 million, giving a free cash flow of -$146.50 million.

Operating Cash Flow	-143.10M
Capital Expenditures	-3.40M
Free Cash Flow	-146.50M
FCF Per Share	-$2.44

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-6,398.81%
Pretax Margin	-7,417.79%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

IGM Biosciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.10%
Shareholder Yield	-8.10%
Earnings Yield	-285.19%
FCF Yield	-210.08%

Analyst Forecast

The average price target for IGM Biosciences is $6.00, which is 417.24% higher than the current price. The consensus rating is "Hold".

Price Target	$6.00
Price Target Difference	417.24%
Analyst Consensus	Hold
Analyst Count	8
Revenue Growth Forecast (5Y)	9.87%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

IGM Biosciences has an Altman Z-Score of -7.74 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.74
Piotroski F-Score	3